Pediatric Blood & Cancer · 2020 · 11 citations · 15 references
MedicineHematologyImmunologyHematologic OncologyStem Cell TransplantationTransplant ImmunologyConditioning RegimensReduced-intensity ConditioningTransplant ComplicationsTransplant OutcomesTransplant SurvivalTransplant-related ToxicitiesAllogeneic Stem Cell TherapyConditioning Regimen IntensityConditioning Regimen ToxicityHematopoietic ChimerismHematopoietic Stem Cell Transplant ConditioningReduced Toxicity ConditioningSecondary Hemophagocytic LymphohistiocytosisTransplantation Outcome Assessment
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH), a rare hyperinflammatory immuneregulatory disorder, is a challenge in hematopoietic stem cell transplantation (HSCT) because of the high rate of mixed chimerism, relapse, and graft failure (GF) unless intensive myeloablative regimens are used. However, historically conventional myeloablative regimens (conv MA) are associated with high toxicity and mortality. PROCEDURE: We retrospectively compared transplant outcomes between three preparative regimens of varying intensities: Conv MA (n = 15), reduced-intensity conditioning (RIC, n = 12), and a treosulfan-based reduced-toxicity conditioning (RTC, n = 9). RESULTS: Patients in the RIC cohort had a higher incidence of mixed donor chimerism and five patients (42%) developed secondary GF (P = .002) compared to the other two regimens. There was a higher incidence of veno-occlusive disease and intensive care unit (ICU) admissions in the Conv MA cohort. With the RTC regimen, there was a similar 2-year overall survival (89, 73, and 83%; P = .87), but improved compound EFS (lack of relapse, GF, second transplant or additional donor cell infusions, or death; 89, 73, and 42%, P = .041) in RTC, Conv MA, and RIC regimen, respectively. CONCLUSIONS: The intensity of the preparative regimen has a significant impact on outcome of HSCT for HLH. The newly described treosulfan-based RTC provides for a stable graft with a reasonable toxicity profile.
15
Graft failure in the modern era of allogeneic hematopoietic SCT
Richard F. Olsson, Mats Remberger, M. Schaffer et al. · Bone Marrow Transplantation · 2012 · 277 citations
Medicine, Hematology, Immunology +12